ACADIA Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 61 to 77.
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating of over 80 as they launch their biggest runs. See if ACADIA Pharmaceuticals can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
While the stock is not near an ideal buy point right now, see if it is able to form and break out from a proper consolidation.
The company posted 0% earnings growth in the latest quarterly report. Sales gains came in at 18%. Keep an eye out for the company's next round of numbers on or around Mar. 3.
ACADIA Pharmaceuticals holds the No. 30 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
